Small molecule · developed by Oculis
OCS-05 is an agent given intravenously for five consecutive days together with standard of care corticosteroid treatment. It is studied in optic neuritis, an inflammatory disease of the optic nerve.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04762017 | Phase 2 | Optic Neuritis | Completed | OCS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Optic Neuritis
Updated Nov 15, 2026. Something wrong or missing? Report it on the OCS page.
See OCS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OCS catalysts and pipeline →